NEW YORK (GenomeWeb News) – Former Life Technologies executive Paul Grossman has joined Telegraph Hill Partners as a venture partner.
Grossman previously was head of global strategy and corporate development at Life Tech, and he also held the same position at Invitrogen. Before he joined Invitrogen, Grossman held a variety of leadership roles at Applied Biosystems, including as a research scientist and patent attorney, VP of intellectual property, and VP of strategy and business development.
Telegraph Hill Partners invests in commercial-stage life science, medical technology, and other healthcare companies, and manages $600 million across three funds.
Annai Systems has named David Szekeres to serve on its board of directors. Szekeres recently was named chief business officer and general counsel at Regulus Therapeutics. He previously was deputy general counsel, chief M&A counsel, and assistant secretary at Life Technologies.
MolecularHealth has added two new members to its US executive team: Tim Cooley and Kevin Krenzke.
Cooley will be senior VP of IT at MolecularHealth. He previously spent 15 years at Eli Lilly, where he held various positions, including director of IT. Krenzke will be senior VP of finance at MolecularHealth. He joins the firm after holding leadership roles at McKesson Specialty Health and US Oncology.
The new additions to the MolecularHealth team come as the company is readying to launch TreatmentMAP, a cancer treatment decision support tool, in the first quarter.
SeraCare Life Sciences said this week it has named Jack Wands to be the founding member of its scientific advisory board.
Wands is a professor of medical science and gastroenterology at Brown Medical School, and he founded the Rhode Island Hospital/Brown University Liver Research Center. His research has centered on the role of Hepatitis B and C infection in the pathogenesis of hepatocellular carcinoma at the molecular level.
KromaTiD, a Fort Collins, Colo.-based molecular cytogenetics company, has hired Alex Vodenlich as its new CEO.
Vodenlich previously served as president and CEO from 2003 to 2011 of Gentel Biosciences, a protein microarray technologies firm that went out of business in early 2012. Prior to GenTel, Vodenlich served as vice president of sales and marketing for PanVera, and before that he was a discovery research scientist for Pfizer and Abbott Laboratories.
Patrick Schnable has been named director of Iowa State University's Plant Sciences Institute.
Schnable is currently a professor in ISU's College of Agriculture and Life Sciences, and received the inaugural chair in genetics in ISU's department of agronomy in 2013.
He also founded and directs the Center for Plant Genomics, a center within the Plant Sciences Institute (PSI) and served as the PSI's associate director 2005 to 2010.
Separately, Schnable is managing partner of Data2Bio, a next-generation sequencing services firm.
The Harrington Discovery Institute and the American Society for Clinical Investigation have awarded the inaugural 2014 Harrington Prize for Innovation in Medicine to Harry Dietz of Johns Hopkins University School of Medicine.
Established this year by the Harrington Discovery Institute at University Hospitals Case Medical Center and ASCI, the award recognizes a physician-scientist who has successfully advanced a biomedical discovery into clinical application. Dietz's research into the origins of Marfan syndrome led to clinical trials, which he directed, of a treatment using a commonly available medication, and his work may lead to a blood test to detect aortas that are at risk for rupture.
The award includes a $20,000 prize, and Dietz will deliver the Harrington Prize Lecture at the 2014 ASCI and Association of American Physicians joint meeting. He also will publish a review in the April issue of the Journal of Clinical Investigation.
Dietz is a professor in the Departments of Medicine, Pediatrics, and Molecular Biology and Genetics at the JHU School of Medicine and director of the William S. Smilow Center for Marfan Syndrome Research.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.